Lung Cancer Diagnosed More Than Five Years after the Development of Polymyositis/Dermatomyositis

Table 2

Profiles of the 5 patients. Only 1 patient had PM, and only 1 patient was positive for anti-Jo1 antibody. Immunosuppressants were coadministered with PSL in 4 patients. Four patients had complication with IP. The histological patterns and stages were diverse. Three patients were heavy smokers.

Case; Age	Myositis	Time from myositis to LK	Anti-Jo1	Treatment for PM/DM (at diagnosis of LK)	IP	Histological pattern	Clinical staging	B.I.
Case 1; 69 y. M	DM	13 y. 9 m.	+	PSL + AZP; (CyA, Tac., mPSL, and CPA)	+	LCNEC	Stage IV	1440; Ex.
Case 2; 47 y. M	DM	7 y. 8 m.	−	PSL + CyA	−	SCLC	Stage IIIA; LD	750; Curr.
Case 3; 69 y. F	PM	5 y. 7 m.	−	PSL + AZP	+	Adeno	Stage IV	0
Case 4; 71 y. F	DM	30 y.	Unknown	PSL	+	Adeno	Stage IV	0
Case 5; 50 y. M	DM	12 y.	−	PSL + CyA	+	SCC	Stage IA	600; Ex.

DM: dermatomyositis; PM: polymyositis; PSL: prednisolone; CyA: ciclospoin; CPA: cyclophosphamide; AZP: azathioprine; Tac: tacrolimus; LCNEC: large cell neuroendocrine carcinoma; SCLC: small cell carcinoma; Adeno: adenocarcinoma; SCC: squamous cell carcinoma; B.I.: Brinkman Index; Ex.: exsmoker; Curr.: current smoker.